Related Experiment Video
Updated: Nov 10, 2025
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
NPM1A in Plasma is a Potential Prognostic Biomarker in Acute Myeloid Leukemia
Chengming Sun1, Yujie Gao1, Liping Yang1
1Yantai Yuhuangding Hospital, Yantai, 264000, ShanDong, China.
Objective:
The aim of the study was to investigate whether nucleophosmin type A mutation (NPM1A) in plasma was associated with the prognosis of patients with acute myeloid leukemia (AML).
Methods:
Plasma NPM1A levels were investigated in 80 AML patients, 22 patients with benign hematopathy and 12 healthy donors by qRT-PCR. Additionally, the relationship between NPM1A levels and clinic characteristics were evaluated by Chi-square test. Kaplan-Meier method was used to analyze overall survival (OS) and relapse-free survival (RFS), and univariate and multivariate analyses were performed with Cox proportional hazard model.
Results:
Plasma levels of NPM1A in AML patients were significantly higher than those in benign hematopathy patients and healthy controls, respectively (both P<0.001). Additionally, high NPM1A level was significantly associated with higher WBC and platelet count (both, P<0.05). Moreover, survival analysis revealed that patients with high NPM1A levels had worse OS (P<0.001) and RFS (P<0.001). Multivariate analysis identified NPM1A as an independent prognostic predictor for AML (OS: HR=8.214, 95% CI: 2.974-22.688, P<0.001; RFS: HR=4.640, 95%CI: 1.825-11.795, P=0.001).
Conclusions:
Results reveal that NPM1A in plasma could serve as an ideal tool for predicting the prognosis of patients with AML.
Insights
Plasma nucleophosmin type A mutation (NPM1A) levels are elevated in acute myeloid leukemia (AML) patients. Higher NPM1A levels indicate a poorer prognosis, suggesting NPM1A as a valuable biomarker for AML patient outcomes.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
- Accurate prognostic markers are crucial for guiding AML treatment strategies.
- The role of plasma biomarkers in AML prognosis requires further investigation.
Purpose of the Study:
- To determine if plasma nucleophosmin type A mutation (NPM1A) levels correlate with the prognosis of AML patients.
- To assess the diagnostic potential of plasma NPM1A in distinguishing AML from other hematologic conditions.
Main Methods:
- Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to measure plasma NPM1A levels in 80 AML patients, 22 benign hematopathy patients, and 12 healthy donors.
- Chi-square tests analyzed the association between NPM1A levels and clinical characteristics.
- Kaplan-Meier and Cox proportional hazard models evaluated overall survival (OS) and relapse-free survival (RFS).
Main Results:
- Plasma NPM1A levels were significantly higher in AML patients compared to benign hematopathy patients and healthy controls (P<0.001).
- Elevated NPM1A levels correlated with higher white blood cell (WBC) and platelet counts (P<0.05).
- High plasma NPM1A was associated with significantly worse OS (P<0.001) and RFS (P<0.001).
Conclusions:
- Plasma NPM1A is a potential biomarker for predicting AML prognosis.
- NPM1A levels are significantly elevated in AML patients and correlate with adverse outcomes.
- This study suggests NPM1A as a promising tool for prognostic assessment in AML.
